Immune checkpoint blockade can reinforce antitumor immunity by hindering intrinsic suppressors (e.g. CTLA4, PD1, or PDL1) from the immunosuppressive microenvironment where the tumor locates while several checkpoint inhibitors have been approved for clinical application (158). Here, CTLA4 is linked to neoplasm.